NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.
Dr. Yong-Jun LIU
Medimmune Names New Head of Research
MedImmune, the global biologics research and development arm of AstraZeneca, has named Yong-Jun Liu, M.D., Ph.D., as the company’s new head of research. Most recently, Dr. Liu served as VP and chief scientific officer at the Baylor Research Institute and director of the Baylor Institute for Immunology Research.
In his new role, Dr. Liu is responsible for driving preclinical research in multiple therapeutic areas to help advance drug candidates from discovery to development.
Dr. Michael FRANKEN
Momenta Pharmaceuticals Appoints President
Biosimilars Business Momenta Pharmaceuticals has named Michael Franken, M.D., as president, biosimilars business. Dr. Franken is responsible with overseeing the operational management of Momenta’s biosimilars program, including its collaboration with Baxter International Inc., strategic planning, P&L responsibility, and other supporting activities. Dr. Franken reports to Craig Wheeler, Momenta’s president and CEO.
Before joining Momenta, Dr. Franken served as senior VP and chief business officer of Radius Health where he was responsible for the company’s commercial, business development, and strategy functions with a focus on its Phase III stage, innovative bone anabolic medicine to treat osteoporosis.
Dr. Robert PIERCE
OncoSec Medical Hires Chief Medical Officer
OncoSec Medical Inc., a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, has named Dr. Robert Pierce chief medical officer.
He joins OncoSec Medical from Merck Research Labs, where he spent almost seven years dedicated to developing disease-oriented and tissue-based translational medicine platforms.
Dr. Pierce is the co-author of more than 50 peer-reviewed journal articles and book chapters, and has been a reviewer for numerous scientific journals as well as National Institutes of Health grants.
Dr. Juergen FROEHLICH
Aradigm Appoints Chief Medical Officer
Aradigm, an emerging specialty pharmaceutical company focused on the development and commercialization of drugs delivered by inhalation for the prevention and treatment of severe respiratory diseases, has appointed Juergen Froehlich, M.D., chief medical officer.
He joins Aradigm from Vertex Pharmaceuticals, where he was head of regulatory affairs, overseeing global submissions and approvals under accelerated review timelines of Kalydeco (ivacaftor) and the granting of two breakthrough designations for the orphan indication of cystic fibrosis.
Dr. Michael FOLEY
Accomplished Scientist Selected to Lead Tri-Institutional Therapeutics Discovery Institute
Michael Foley, Ph.D., has been selected to lead the Tri-Institutional Therapeutics Discovery Institute Inc. (Tri-I TDI), a pioneering collaboration of Weill Cornell Medical College, The Rockefeller University, and Memorial Sloan-Kettering Cancer Center that is designed to expedite early-stage drug discovery into novel treatments for patients.
Dr. Foley’s title is the Sanders Director of Tri-I TDI and director of its Sanders Innovation and Education Initiative, in recognition of the $15 million gift from Lewis and Ali Sanders to help establish the Institute.
An accomplished chemist and entrepreneur with more than 25 years of industry and academic experience, Dr. Foley is scientific co-founder of four companies and one academic institute and has placed 12 single-agent or combination drugs into clinical development. He was most recently the director of the chemical biology platform at the Broad Institute of Harvard and MIT, which successfully established more than 150 high throughput screening development collaborations under his leadership.
Dudnyk, a full-service advertising agency, has named Tim Anderson, VP, account director. He spent the last four-plus years at Flashpoint Medica.
Mr. Anderson has significant experience launching both U.S. and global products with a specialized focus in oncology.
Kristen Casey joins the Dudnyk account team as a VP, account director. She brings a unique background to the team, having practiced for several years as a psychologist and child and family therapist, before transitioning into pharmaceutical sales and product management. Then, in 2007, Ms. Casey transitioned into an account leadership role on the agency side within the Publicis Group before joining Dudnyk.
CircleScience Names VP, Client Services
Jackie Richards has been named VP, client services, at CircleScience, a division of KnowledgePoint360 Group, a healthcare information and communications agency. Ms. Richards has worked in medical education and communications since joining KnowledgePoint360 in 2001, initially working within the Gardiner-Caldwell Communications division before moving to CircleScience in January 2012.
Scott EVANGELISTA Quintiles Appoints President, Integrated Commercial Services and Solutions
Quintiles has appointed W. Scott Evangelista to serve as president, Integrated Commercial Services and Solutions. In this role, Mr. Evangelista is responsible for leading Quintiles’ global commercial organization and the ongoing development and delivery of its related service offerings.
A veteran of the life-sciences industry with more than two decades of experience, Mr. Evangelista joins Quintiles, a provider of biopharmaceutical development and commercial outsourcing services, from Deloitte Consulting. At Deloitte, he was a principal in the company’s life-sciences practice where he served as commercial practice leader. In this role, he worked with biopharmaceutical customers across a spectrum of commercial operations, providing strategic consulting, business development, and overall management guidance.
Gail FOWLER Rho Names VP of Operations
Gail Fowler joins Rho, a privately held CRO, as VP of operations, bringing almost 30 years of clinical research experience. Ms. Fowler’s most recent position was VP of clinical operations and clinical trial management for ICON Clinical Research.
Jim BEACH Camargo Names Chief Operating Officer
Jim Beach has been named chief operating officer of Carmargo Pharmaceutical Services, a drug development organization.
Before joining Camargo, Mr. Beach had been VP of marketing and product management for scientific products for Cardinal Health.
OmniComm Bolsters Organization With Addition of Two Industry Experts
OmniComm Systems, which specializes in the EDC marketplace, has made two additions to the organization.
John Fontenault has joined OmniComm as VP of operations. A clinical data operations and data systems executive and 24-year veteran of the pharmaceutical industry, he brings a depth of practical expertise to OmniComm. Most recently, he was VP, operations, at ER Squared.
Michelle King has joined OmniComm as director, early phase consulting. Ms. King comes to OmniComm from Instem, formerly Logos Technologies, and brings more than a decade of hands-on research experience.
Dr. Jonathan GOLDMAN
Aptuit Names CEO
Aptuit LLC has appointed Jonathan Goldman, M.D. as CEO. Dr. Goldman is focusing his efforts on the growth of Aptuit as a provider of outsourced services in the early development space by establishing new partnerships with clients and pursuing strategic acquisitions.
He joins the company from ICON Clinical Research. Talent Pool executive appointments and promotions in the healthcare industry.